Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment...(tent is that these discussions willallow...),Health

Stephen Pflugfelder, M.D., an expert in dry eye at Baylor College of Medicine in Houston added: "The results of this study add to the growing body of evidence that topical doxycycline therapy could be an important new treatment modality for patients with dry eye disease."

The 160-patient Phase 2 trial was a 56-day, double-masked, randomized, parallel-group study designed to assess the safety and efficacy of ALTY-0501. Patients with dry eye disease were exposed to a controlled adverse environment on day 1 and asked to self-administer either ALTY-0501 eye drops or vehicle eye drops (placebo) four times per day. Patients were subsequently exposed to the controlled adverse environment on days 28 and 56. Environmental damage was measured by fluorescein staining. Symptoms were assessed daily in patient diaries throughout the study period.

ALTY-0501 is a proprietary topical formulation of 0.025% doxycycline in a non-antimicrobial dose, which acts to inhibit matrix metalloproteinase-9 (MMP-9). It provides effective concentrations of the drug directly to ocular surface cells of patients suffering from dry eye disease. By inhibiting MMP-9, ALTY-0501 is expected to prevent the disruption of the epithelial barrier on the ocular surface. Alacrity acquired the worldwide rights to the drug candidate from the University of Miami when the company was formed in 2005.

Alacrity is a clinical stage pharmaceutical company focused exclusively on developing and commercializing differentiated therapeutics to address unmet needs in the most significant ophthalmic diseases. For more information, visit http://www.alacritybio.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statement
'/>"/>